Editas Medicine Inc - ESG Rating & Company Profile powered by AI
This webpage of Editas Medicine Inc was assembled by All Street Sevva using cutting edge artificial intelligence. The webpage displays a zero-cost E,S&G report for Editas Medicine Inc. Alternative corporations in the scoring industry group for Editas Medicine Inc are displayed.
Editas Medicine Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.8; made up of an environmental score of 4.0, social score of 3.4 and governance score of 4.0.
3.8
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1089 | Zymeworks Inc | 3.9 | Medium |
| 1089 | bluebird bio Inc | 3.9 | Medium |
| 1112 | Editas Medicine Inc | 3.8 | Medium |
| 1112 | AcelRx Pharmaceuticals Inc | 3.8 | Medium |
| 1112 | Arcus Biosciences Inc | 3.8 | Medium |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Editas Medicine Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Editas Medicine Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Editas Medicine Inc report the average age of the workforce?
Sign up for free to unlockDoes Editas Medicine Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Editas Medicine Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Editas Medicine Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Editas Medicine Inc offer flexible work?
Sign up for free to unlockDoes Editas Medicine Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Editas Medicine Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Editas Medicine Inc conduct supply chain audits?
Sign up for free to unlockDoes Editas Medicine Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Editas Medicine Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Editas Medicine Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Editas Medicine Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Editas Medicine Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Editas Medicine Inc disclose water use targets?
Sign up for free to unlockDoes Editas Medicine Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Editas Medicine Inc have a product recall in the last two years?
Sign up for free to unlockDoes Editas Medicine Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Editas Medicine Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Editas Medicine Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Editas Medicine Inc disclose parental leave metrics?
Sign up for free to unlockDoes Editas Medicine Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Editas Medicine Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Editas Medicine Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Editas Medicine Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Editas Medicine Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Editas Medicine Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Editas Medicine Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Editas Medicine Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Editas Medicine Inc disclose its waste policy?
Sign up for free to unlockDoes Editas Medicine Inc report according to TCFD requirements?
Sign up for free to unlockDoes Editas Medicine Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Editas Medicine Inc disclose energy use targets?
Sign up for free to unlockDoes Editas Medicine Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Editas Medicine Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Editas Medicine Inc
These potential risks are based on the size, segment and geographies of the company.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads to inherited childhood blindness. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumor cancers; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has an early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and research collaboration with Asklepios BioPharmaceutical, Inc. to develop a therapy to treat a neurological disease, as well as research collaboration with AskBio. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.